Eradicating hematologicalcancers at their root causes
Building a world class heme-oncology company
Hematological cancers encompass a diverse group of cancers affecting the blood, bone marrow, and lymphatic systems and continue to present significant unmet medical need despite advancements in treatment options.
Stelexis BioSciences is a clinical-stage biopharmaceutical company created to accelerate novel treatments that aim to eradicate hematological malignancies at their root causes to drive better outcomes for patients.
Our Science
Our pipeline programs address novel targets for hematological malignancies where there is a pressing need for novel therapies that can induce remissions, prevent relapse, improve patient outcomes and ultimately survival.
We are developing novel medicines for acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), lower-risk MDS, myeloproliferative neoplasms and systemic mastocytosis, among others.
Our Pipeline